Cart
sales@molnova.com
Girentuximab
CAS No. 916138-87-9
Girentuximab( —— )
Catalog No. M36663 CAS No. 916138-87-9
Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPUP).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 337 | Get Quote |
|
| 5MG | 558 | Get Quote |
|
| 10MG | 896 | Get Quote |
|
| 100MG | 2277 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGirentuximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionGirentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPUP).
-
DescriptionGirentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetCarbonic Anhydrase
-
RecptorCarbonic Anhydrase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number916138-87-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3(7):913-920. ?
molnova catalog
related products
-
hCAIX-IN-5
hCAIX-IN-5 was a selective hCAIX inhibitor, inhibiting hCAI, hCAII, hCAIV, and hCAIX with Ki values of >10000, >10000, 130.7, and 829.1 nM, respectively.
-
Hydrochlorothiazide
Hydrochlorothiazide is a first line diuretic compound of the thiazide class.
-
Levosimendan
Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC), provides treatment for heart failure.
